sacituzumab govitecan
gilead sciences
['bcsm', 'tropics-02', 'trodelvy']
a bit surprised to see the benefit in tropics-02 is 4 vs. 5.5 months. want to see the full data and what percentage have durable benefit. #bcsm #asco22 asco 2022 the tropical wind blows cold for trodelvy | evaluate 
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.